{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T09:32:23Z","timestamp":1760866343773,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["VIR\/18\/2018\/ECD-I"],"award-info":[{"award-number":["VIR\/18\/2018\/ECD-I"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jceh.2021.06.023","type":"journal-article","created":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T11:14:48Z","timestamp":1625310888000},"page":"669-671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Use of Sofosbuvir\/Velpatasvir\/Voxilaprevir for Sofosbuvir Nonresponder Genotype 3 HCV Infection in India"],"prefix":"10.1016","volume":"12","author":[{"given":"Prachi","family":"Tiwari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harshita","family":"Katiyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praveer","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3525-9381","authenticated-orcid":false,"given":"Amit","family":"Goel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2021.06.023_bib1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1055\/s-0039-1687823","article-title":"Retreatment of hepatitis C virus-infected patients\u00a0with direct-acting antiviral failures","volume":"39","author":"Pawlotsky","year":"2019","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jceh.2021.06.023_bib2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.7326\/0003-4819-157-8-201210160-00006","article-title":"Accuracy of rapid and point-of-care screening tests for hepatitis C: a systematic review and meta-analysis","volume":"157","author":"Shivkumar","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jceh.2021.06.023_bib3","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/apt.12646","article-title":"Review article: HCV genotype 3 - the new treatment challenge","volume":"39","author":"Ampuero","year":"2014","journal-title":"Aliment Pharmacol Therapeut"},{"key":"10.1016\/j.jceh.2021.06.023_bib4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/jgh.14466","article-title":"Burden of hepatitis C virus infection in India: a systematic review and meta-analysis","volume":"34","author":"Goel","year":"2019","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2021.06.023_bib5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12664-017-0763-3","article-title":"Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: an Indian experience","volume":"36","author":"Goel","year":"2017","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.jceh.2021.06.023_bib6","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jhep.2019.07.006","article-title":"Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting","volume":"71","author":"Dhiman","year":"2019","journal-title":"J\u00a0Hepatol"},{"year":"2020","series-title":"Acute Hepatitis C Treatment in Advanced Renal Failure Using 8 Weeks of Pan-Genotypic Daclatasvir and Reduced-Dose Sofosbuvir","author":"Goel","key":"10.1016\/j.jceh.2021.06.023_bib7"},{"key":"10.1016\/j.jceh.2021.06.023_bib8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/nep.13222","article-title":"Daclatasvir and reduced-dose sofosbuvir: an effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL\/min","volume":"24","author":"Goel","year":"2019","journal-title":"Nephrology"},{"key":"10.1016\/j.jceh.2021.06.023_bib9","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.cld.2015.06.005","article-title":"Mechanisms of virologic failure with direct-acting antivirals in hepatitis C and strategies for retreatment","volume":"19","author":"Costilla","year":"2015","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2021.06.023_bib10","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.11.007","article-title":"Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals","volume":"154","author":"Dietz","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2021.06.023_bib11","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1111\/liv.14797","article-title":"Resistance Analysis and Treatment Outcomes in Hepatitis C Virus Genotype 3-infected Patients within the Italian Network VIRONET-C","volume":"41","author":"Di Maio","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2021.06.023_bib12","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1002\/jmv.26971","article-title":"Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C","volume":"93","author":"Elhence","year":"2021","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.jceh.2021.06.023_bib13","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"N\u00a0Engl J Med"},{"year":"2016","series-title":"Vosevi\u2122 (Sofosbuvir\/Velpatasvir\/Voxilaprevir) Tablets 400 mg\/100 mg\/100 mg [product Monograph]","key":"10.1016\/j.jceh.2021.06.023_bib14"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688321001675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688321001675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:08:36Z","timestamp":1760854116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688321001675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0973688321001675"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2021.06.023","relation":{},"ISSN":["0973-6883"],"issn-type":[{"type":"print","value":"0973-6883"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Sofosbuvir\/Velpatasvir\/Voxilaprevir for Sofosbuvir Nonresponder Genotype 3 HCV Infection in India","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2021.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}